Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Valneva's 2024 Guidance: Expects Product Sales Of €150M-€180M, Reflecting Continued Revenue Growth For Proprietary Products And IXCHIQ®'S Launch-Year Sales

Author: Benzinga Newsdesk | February 15, 2024 02:36am

First full year 2024 guidance

  • Product sales expected between €150 million and €180 million, reflecting continued revenue growth for proprietary products and IXCHIQ®'s launch-year sales, despite anticipated supply constraints for third-party products and IXIARO®
  • Other income anticipated between €95 million and €105 million, including the PRV sold in early 2024 for €95 million
  • Expected R&D expenses between €65 million and €90 million

Posted In: VALN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist